ATTENTION DEFICIT HYPERACTIVITY DISORDER COMBINED
Clinical trials for ATTENTION DEFICIT HYPERACTIVITY DISORDER COMBINED explained in plain language.
Never miss a new study
Get alerted when new ATTENTION DEFICIT HYPERACTIVITY DISORDER COMBINED trials appear
Sign up with your email to follow new studies for ATTENTION DEFICIT HYPERACTIVITY DISORDER COMBINED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New ADHD pill aims to control symptoms for 16 hours
Disease control CompletedThis phase 3 trial tests whether a new formulation of dexmethylphenidate (CTx-1301) can improve attention and reduce ADHD symptoms in adults for up to 16 hours. Participants take an optimized dose (25, 37.5, or 50 mg) and complete math tests in a simulated classroom. The study co…
Matched conditions: ATTENTION DEFICIT HYPERACTIVITY DISORDER COMBINED
Phase: PHASE3 • Sponsor: Cingulate Therapeutics • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New ADHD drug shows promise for kids in Late-Stage trial
Symptom relief CompletedThis study tested a new medication called CTx-1301 (dexmethylphenidate) for children and teens aged 6 to 17 with ADHD. The goal was to see if it reduces ADHD symptoms better than a placebo. 103 participants took either the drug or a placebo, and researchers measured changes in AD…
Matched conditions: ATTENTION DEFICIT HYPERACTIVITY DISORDER COMBINED
Phase: PHASE3 • Sponsor: Cingulate Therapeutics • Aim: Symptom relief
Last updated Jun 27, 2026 08:12 UTC